Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.68 USD
Change Today 0.00 / 0.00%
Volume 431.0K
As of 1:57 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi cvr (GCVRZ) Snapshot

Open
$0.67
Previous Close
$0.68
Day High
$0.68
Day Low
$0.66
52 Week High
11/17/14 - $1.06
52 Week Low
04/1/14 - $0.30
Market Cap
--
Average Volume 10 Days
690.0K
EPS TTM
--
Shares Outstanding
238.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANOFI CVR (GCVRZ)

sanofi cvr (GCVRZ) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi cvr (GCVRZ) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2014.

sanofi cvr (GCVRZ) Key Developments

Ministry of Health Saudi Arabia Signs Cooperation Agreement with Sanofi

The Ministry of Health has entered into a cooperation agreement with Sanofi. The agreement is aimed at helping health care professionals with continuous training for diabetes education in primary care sector, medical research in the area of diabetes and good clinical practice (GCP) training program. Sanofi is partnering up with the MoH and other authorities focusing on continuous medical education for primary care physicians, medical research particularly in type 2 diabetes and GCP training program for health care professionals.

Selecta Biosciences, Inc., JDRF and Sanofi Extends Collaboration to Develop Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. Selectas proprietary tolerogenic SVP products show potential to re-educate the immune system to stop or suppress pro-inflammatory responses against a specific antigen, thereby halting the undesirable immune reaction without causing harmful global immune suppression common with general immune system modulating drugs. As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells. JDRF has a strategic research plan designed to deliver a sustained stream of new, life-changing therapies.

Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 Through 6 Years of Age

Sanofi Pasteur, the vaccines division of Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. To protect infants and children from life-threatening diseases, the Centers for Disease Control and Prevention (CDC) recommend children 4 through 6 years of age receive both their fifth dose of the diphtheria, tetanus and acellular pertussis (DTaP) vaccine series and their fourth dose of inactivated poliovirus (IPV) vaccine series.1 Quadracel vaccine can be administered as a fifth dose in the DTaP series and as a fourth or fifth dose in the IPV series in children 4 through 6 years of age. This FDA approval is based on data from a pivotal multicenter, randomized, controlled, Phase III study designed to compare the safety and immunogenicity of Quadracel vaccine (DTaP-IPV) with DAPTACEL (DTaP) and IPOL (IPV) vaccines in children 4 through 6 years of age who were previously vaccinated with DAPTACEL and/or Pentacel (DTaP-IPV/Hib) vaccines. Results show Quadracel vaccine has similar safety and immunogenicity profiles as compared to those of separately administered DAPTACEL and IPOL vaccines.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GCVRZ:US $0.68 USD 0.00

GCVRZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $293.94 USD -3.68
Amgen Inc $155.68 USD -4.17
Bayer AG €141.30 EUR +1.94
Gilead Sciences Inc $96.76 USD -1.37
Novo Nordisk A/S kr377.00 DKK +5.00
View Industry Companies
 

Industry Analysis

GCVRZ

Industry Average

Valuation GCVRZ Industry Range
Price/Earnings 25.2x
Price/Sales 3.2x
Price/Book 1.9x
Price/Cash Flow 15.9x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI CVR, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.